An update on current pharmacotherapy options for dyspepsia

Baharak Moshiree, Jose Barboza, Nicholas Talley

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Functional dyspepsia (FD) is a highly prevalent and challenging disorder which impacts patients' quality of life and poses a considerable socioeconomic burden. Given the vagueness of the definition of FD based on the current Rome III criteria's expert opinion, the diagnosis of FD continues to be one of exclusion. Despite efforts to better define what constitutes FD, validity of such diagnostic criteria remains controversial given the lack of a distinct pathophysiologic mechanism. Areas covered: New insights into the pathophysiology of FD have expanded our treatment options for the syndrome. This review will discuss the current pharmacologic treatments of FD with particular focus on the more robust randomized controlled trials to date. Expert opinion: Recently, the understanding of the pathophysiology of FD has evolved with novel hypothesis such as sensorimotor abnormalities of the stomach or duodenum, genetic polypmorphisms, psychological comorbidities, food sensitivities and allergies, and immune dysregulation found to be possibly responsible for its pathogenesis. Despite the expanding knowledge about the likely multifactorial pathophysiology of FD, its treatment remains a challenge.

Original languageEnglish
Pages (from-to)1737-1753
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number13
DOIs
StatePublished - Sep 1 2013

Fingerprint

Dyspepsia
Drug Therapy
Expert Testimony
Food Hypersensitivity
Duodenum
Comorbidity
Stomach
Therapeutics
Randomized Controlled Trials
Quality of Life
Psychology

Keywords

  • Epigastric pain syndrome
  • Functional dyspepsia
  • Functional gastroduodenal disorder
  • Postprandial distress syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

An update on current pharmacotherapy options for dyspepsia. / Moshiree, Baharak; Barboza, Jose; Talley, Nicholas.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 13, 01.09.2013, p. 1737-1753.

Research output: Contribution to journalArticle

Moshiree, Baharak ; Barboza, Jose ; Talley, Nicholas. / An update on current pharmacotherapy options for dyspepsia. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 13. pp. 1737-1753.
@article{765de98b7de24df685243584072cd8a1,
title = "An update on current pharmacotherapy options for dyspepsia",
abstract = "Introduction: Functional dyspepsia (FD) is a highly prevalent and challenging disorder which impacts patients' quality of life and poses a considerable socioeconomic burden. Given the vagueness of the definition of FD based on the current Rome III criteria's expert opinion, the diagnosis of FD continues to be one of exclusion. Despite efforts to better define what constitutes FD, validity of such diagnostic criteria remains controversial given the lack of a distinct pathophysiologic mechanism. Areas covered: New insights into the pathophysiology of FD have expanded our treatment options for the syndrome. This review will discuss the current pharmacologic treatments of FD with particular focus on the more robust randomized controlled trials to date. Expert opinion: Recently, the understanding of the pathophysiology of FD has evolved with novel hypothesis such as sensorimotor abnormalities of the stomach or duodenum, genetic polypmorphisms, psychological comorbidities, food sensitivities and allergies, and immune dysregulation found to be possibly responsible for its pathogenesis. Despite the expanding knowledge about the likely multifactorial pathophysiology of FD, its treatment remains a challenge.",
keywords = "Epigastric pain syndrome, Functional dyspepsia, Functional gastroduodenal disorder, Postprandial distress syndrome",
author = "Baharak Moshiree and Jose Barboza and Nicholas Talley",
year = "2013",
month = "9",
day = "1",
doi = "10.1517/14656566.2013.809063",
language = "English",
volume = "14",
pages = "1737--1753",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - An update on current pharmacotherapy options for dyspepsia

AU - Moshiree, Baharak

AU - Barboza, Jose

AU - Talley, Nicholas

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Introduction: Functional dyspepsia (FD) is a highly prevalent and challenging disorder which impacts patients' quality of life and poses a considerable socioeconomic burden. Given the vagueness of the definition of FD based on the current Rome III criteria's expert opinion, the diagnosis of FD continues to be one of exclusion. Despite efforts to better define what constitutes FD, validity of such diagnostic criteria remains controversial given the lack of a distinct pathophysiologic mechanism. Areas covered: New insights into the pathophysiology of FD have expanded our treatment options for the syndrome. This review will discuss the current pharmacologic treatments of FD with particular focus on the more robust randomized controlled trials to date. Expert opinion: Recently, the understanding of the pathophysiology of FD has evolved with novel hypothesis such as sensorimotor abnormalities of the stomach or duodenum, genetic polypmorphisms, psychological comorbidities, food sensitivities and allergies, and immune dysregulation found to be possibly responsible for its pathogenesis. Despite the expanding knowledge about the likely multifactorial pathophysiology of FD, its treatment remains a challenge.

AB - Introduction: Functional dyspepsia (FD) is a highly prevalent and challenging disorder which impacts patients' quality of life and poses a considerable socioeconomic burden. Given the vagueness of the definition of FD based on the current Rome III criteria's expert opinion, the diagnosis of FD continues to be one of exclusion. Despite efforts to better define what constitutes FD, validity of such diagnostic criteria remains controversial given the lack of a distinct pathophysiologic mechanism. Areas covered: New insights into the pathophysiology of FD have expanded our treatment options for the syndrome. This review will discuss the current pharmacologic treatments of FD with particular focus on the more robust randomized controlled trials to date. Expert opinion: Recently, the understanding of the pathophysiology of FD has evolved with novel hypothesis such as sensorimotor abnormalities of the stomach or duodenum, genetic polypmorphisms, psychological comorbidities, food sensitivities and allergies, and immune dysregulation found to be possibly responsible for its pathogenesis. Despite the expanding knowledge about the likely multifactorial pathophysiology of FD, its treatment remains a challenge.

KW - Epigastric pain syndrome

KW - Functional dyspepsia

KW - Functional gastroduodenal disorder

KW - Postprandial distress syndrome

UR - http://www.scopus.com/inward/record.url?scp=84881627425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881627425&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.809063

DO - 10.1517/14656566.2013.809063

M3 - Article

C2 - 23777571

AN - SCOPUS:84881627425

VL - 14

SP - 1737

EP - 1753

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 13

ER -